You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immuno-oncology therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)

Not yet recruiting
  • Gastroesophageal Adenocarcinoma
  • toripalimab FOLFOX
  • (no location specified)
Aug 3, 2023

Cabozantinib Post First-line Immuno-oncology Checkpoint

Completed
  • Advanced Renal Cell Carcinoma (aRCC)
    • Glasgow, United Kingdom
    • +8 more
    Jun 30, 2022

    Learn About First and Later Lines of Medicines in Treating

    Completed
    • Metastatic Renal Cell Carcinoma
      • New York, New York
        Pfizer Headquarters
      May 12, 2023

      ApricityRx™ for Management of IR-AEs in Patients on

      Recruiting
      • Cancer
      • ApricityRx mobile application
      • New York, New York
        Columbia University Irving Medical Center
      Sep 25, 2020

      Urine Omics Predicting IO Therapy Responses in mRCC Patients

      Recruiting
      • Metastatic Renal Cell Carcinoma
      • No intervention required
      • Taipei, Taiwan
        National Taiwan University Hospital
      Jan 18, 2022

      Urine Omics Predicting IO Therapy Responses in mUC Patients

      Recruiting
      • Metastatic Urothelial Carcinoma
      • No intervention required
      • Taipei, Taiwan
        National Taiwan University Hospital
      Dec 19, 2021

      Cancer Trial in Chicago (Nivolumab, Cabiralizumab, Urelumab)

      Active, not recruiting
      • Cancer
      • Chicago, Illinois
        University of Chicago Medical Center
      Mar 14, 2022

      Kidney Cancer, Clear Cell Renal Cell Carcinoma Metastatic, Synchronous Tumor Trial in Seoul (Cytoreductive

      Recruiting
      • Kidney Cancer
      • +2 more
      • Cytoreductive nephrectomy±metastasectomy
      • Human-derived materials sampling
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Mar 2, 2023

      Biospecimen Procurement for Center for Immuno-Oncology

      Recruiting
      • Multiple Myeloma
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        Jul 13, 2022

        Solid Tumor, Adult Trial in United States (IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy)

        Recruiting
        • Solid Tumor, Adult
        • Scottsdale, Arizona
        • +5 more
        Apr 14, 2022

        NSCLC Patients Trial in Marseille (procedure, diagnostic test, other)

        Recruiting
        • Non-small Cell Lung Cancer Patients
        • BIOPSY
        • +2 more
        • Marseille, France
          Assistance Pubique Hopitaux de Marseille
        Sep 21, 2022

        Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult Trial in Worldwide (Nivolumab, Relatlimab)

        Recruiting
        • Hepatocellular Carcinoma
        • +4 more
        • Nivolumab
        • Relatlimab
        • Ciudad de Buenos Aires, Buenos Aires, Argentina
        • +74 more
        Nov 11, 2022

        Metastatic Melanoma Trial in Worldwide (LGX818, MEK162, Nivolumab)

        Active, not recruiting
        • Metastatic Melanoma
        • Salzburg, AT, Austria
        • +29 more
        Feb 23, 2022

        Burnout, Professional Trial in Semarang (Traditional Music Therapy)

        Not yet recruiting
        • Burnout, Professional
        • Traditional Music Therapy
        • Semarang, Jawa Tengah, Indonesia
          RSUP dr. Kariadi Semarang
        Nov 12, 2023

        Malignancy, Immune System Diseases, Autoimmune Diseases Trial in Chapel Hill (Biospecimen Collection, Medical Chart Review,

        Recruiting
        • Malignancy
        • +2 more
        • Biospecimen Collection
        • +2 more
        • Chapel Hill, North Carolina
          Lineberger Comprehensive Cancer Center at University of North Ca
        Feb 11, 2022

        NSCLC Trial in Marseille (Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447))

        Recruiting
        • Non-small Cell Lung Cancer
        • Durvalumab (MEDI4736)
        • +5 more
        • Marseille, France
          Assistance Publique Hopitaux de Marseille
        Sep 21, 2022

        Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma Trial in United States (XL092,

        Recruiting
        • Renal Cell Carcinoma
        • +3 more
        • Tucson, Arizona
        • +3 more
        Mar 30, 2022

        Solid Tumor Trial in Beijing (GLS-012, GLS-010)

        Recruiting
        • Solid Tumor
        • Beijing, China
          Beijing Cancer Hospital
        Jun 11, 2023

        Circulating Tumor DNA Kinetics in Immuno-oncology

        Completed
        • Head and Neck Cancer
        • +4 more
          • Toronto, Ontario, Canada
            Princess Margaret Cancer Centre
          May 16, 2022

          Renal Cell Carcinoma Trial in Amsterdam, London (Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab)

          Recruiting
          • Renal Cell Carcinoma
          • Neoadjuvant nivolumab
          • +2 more
          • Amsterdam, NH, Netherlands
          • +1 more
          May 3, 2022

          Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

          Not yet recruiting
          • Inflammatory Arthritis
          • Immune-related Adverse Event
          • (no location specified)
          Sep 13, 2023

          Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

          Not yet recruiting
          • Multiple Myeloma
          • Miami, Florida
            University of Miami
          Oct 20, 2023

          Cancer Trial in Dallas

          Recruiting
          • Cancer
            • Dallas, Texas
              Baylor Scott & White Research Institute
            May 11, 2022

            Malignant Solid Tumor Trial in Worldwide (BMS-986179, Nivolumab, rHuPH20)

            Completed
            • Malignant Solid Tumor
            • BMS-986179
            • +2 more
            • Chicago, Illinois
            • +23 more
            May 25, 2022

            Learn More About How WellTreatment Works When Given After

            Not yet recruiting
            • Unresectable Hepatocellular Carcinoma
            • Baltimore, Maryland
            • +19 more
            Oct 31, 2023